Breakdown | ||||
Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
31.05B | 44.35B | 45.10B | 29.97B | 18.48B | Gross Profit |
1.09B | 5.84B | 9.91B | 4.70B | -1.03B | EBIT |
-1.01B | 3.57B | 7.83B | 2.54B | -3.08B | EBITDA |
2.25B | 10.60B | 14.92B | 4.19B | -5.26B | Net Income Common Stockholders |
-3.71B | 866.77M | 7.56B | -3.16B | -11.18B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
262.00M | 12.01B | 32.84B | 11.48B | 6.54B | Total Assets |
60.08B | 171.00B | 139.53B | 83.37B | 70.23B | Total Debt |
8.31B | 34.86B | 17.62B | 20.41B | 46.79B | Net Debt |
8.05B | 22.85B | -15.22B | 8.94B | 40.25B | Total Liabilities |
10.41B | 47.20B | 26.26B | 32.94B | 60.29B | Stockholders Equity |
49.67B | 53.63B | 50.41B | 30.61B | 9.94B |
Cash Flow | Free Cash Flow | |||
-24.15B | -34.46B | -21.60B | -4.41B | -10.46B | Operating Cash Flow |
4.01B | 12.20B | 6.60B | 2.26B | 85.00M | Investing Cash Flow |
-28.75B | -47.08B | -28.33B | -2.37B | -14.62B | Financing Cash Flow |
17.28B | 13.86B | 41.69B | 8.88B | 4.53B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | ¥43.26B | 9.72 | 1.26% | 8.33% | 10.87% | ||
73 Outperform | ¥20.85B | 10.35 | 3.19% | 10.29% | 50.64% | ||
73 Outperform | ¥5.90B | 27.93 | 3.00% | 2.75% | -22.26% | ||
66 Neutral | $4.47B | 12.21 | 5.40% | 3.65% | 4.14% | -12.00% | |
56 Neutral | ¥25.90B | ― | ― | 27.06% | -473.48% | ||
47 Neutral | ¥13.92B | 9.97 | ― | ― | ― |
W-SCOPE Corporation has reported non-operating expenses for the first quarter of the fiscal year ending January 2026, amounting to 1,347 million yen due to equity losses from its affiliate, W-SCOPE CHUNGJU PLANT CO., LTD. This financial development may impact the company’s financial results and has been detailed in their consolidated financial results announcement.
W-SCOPE Corporation announced an extension of the exercise period for its 3rd stock acquisition rights from April 30, 2025, to April 30, 2030. This decision, approved at the 20th Ordinary General Meeting of Shareholders, is intended to maintain motivation and prevent insider trading while avoiding stock dilution. The extension is not expected to impact the company’s business performance.
W-SCOPE Corporation’s subsidiary, W-SCOPE KOREA CO., LTD., has secured a significant order for bipolar electrodialysis (BPED) modules from POSCO Pilbara Lithium Solution, a joint venture between POSCO Holdings and Philbara Minerals Ltd. This order, valued at approximately 1 billion JPY, is part of a larger project to supply a lithium hydroxide chemical plant in South Korea, which will enhance the country’s capacity to produce lithium hydroxide for electric vehicle batteries. The deal signifies W-SCOPE’s growing influence in the lithium processing industry and is expected to contribute positively to the company’s earnings forecast, with stable demand anticipated due to increased production volumes.
W-SCOPE Corporation has announced an extension of the exercise period for its first and second series of stock acquisition rights, originally issued in 2010 and 2011. This decision aims to maintain motivation and responsibility among stakeholders while preventing insider trading and stock dilution. The extension moves the deadline to April 30, 2030, and is not expected to impact the company’s business performance.